High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, non-randomized, non-controlled clinical trial was conducted to examine the clinical outcomes achieved by using initial high-dose intravitreal ganciclovir injections of ganciclovir in treating cytomegalovirus (CMV) retinitis in patients without human immunodeficiency virus (HIV) infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aier School of Ophthalmology, Central South University
• Treatments: Ganciclovir; Ganciclovir triphosphate

Criteria

Inclusion Criteria:

• Patients with CMVR by ophthalmological examination

• Positive CMV-DNA in aqueous humor approved by real-time PCR.

• HIV-negative.

Exclusion Criteria:

• Diabetic retinopathy,

• Glaucoma.

• Optic neuritis.